During the past decade, University of Kansas Cancer Center conducted 96 clinical trials. In the 10-year time frame, 96 clinical trials started and 38 clinical trials were completed, i.e. on average, 39.6% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 31 clinical trials were completed. i.e. 88.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Kansas Cancer Center" #1 sponsor was "Pfizer" with 9 trials, followed by "Seagen Inc." with 9 trials sponsored, "University of Kansas Medical Center" with 9 trials sponsored, "Incyte Corporation" with 5 trials sponsored and "Bristol-Myers Squibb" with 5 trials sponsored. Other sponsors include 79 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Kansas Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "Myeloproliferative Disorders-Research Consortium" with 3 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 2 trials as a collaborator and "Celgene Corporation" with 2 trials as a collaborator. Other collaborators include 53 different institutions and companies that were collaborators in the rest 52 trials.

According to Clinical.Site data, the most researched conditions in "University of Kansas Cancer Center" are "Acute Myeloid Leukemia" (12 trials), "Breast Cancer" (8 trials), "Multiple Myeloma" (7 trials), "Pancreatic Cancer" (7 trials) and "Acute Lymphoblastic Leukemia" (4 trials). Many other conditions were trialed in "University of Kansas Cancer Center" in a lesser frequency.

Most popular intervention types in "University of Kansas Cancer Center" are "Drug" (99 trials), "Biological" (25 trials), "Other" (9 trials), "Device" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Gemcitabine" (7 trials), "Nivolumab" (6 trials), "Cyclophosphamide" (5 trials) and "Azacitidine" (4 trials). Other intervention names were less common.

The vast majority of trials in "University of Kansas Cancer Center" are 108 trials for "All" genders, 9 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "University of Kansas Cancer Center". undefined are not yet recruiting, 29 are recruiting, 27 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in University of Kansas Cancer Center, undefined suspended trials, and 23 terminated clinical trials to date.

Out of the total trials that were conducted in University of Kansas Cancer Center, 28 "Phase 1" clinical trials were conducted, 61 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".